3SBioSTU:83B -3.21%90 FCF Margin % is 62.32% as of Dec. 2025, which is 238% above its 10-year median of 18.44. GuruFocus rates STU:83B with a GF Score™ of 90/100 and a GF Value™ of €1.51 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, 3SBio ranks better than 96.98% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. 3SBio's Free Cash Flow for the
six
months ended in Dec. 2025 was €1,008 Mil. 3SBio's Revenue for the
six
months ended in Dec. 2025 was €1,618 Mil. Therefore, 3SBio's FCF Margin % for the quarter that ended in Dec. 2025 was 62.32%.
The historical rank and industry rank for 3SBio's FCF Margin % or its related term are showing as below:
STU:83B'
s FCF Margin % Range Over the Past 10 Years
Min: 6.5 Med: 18.44 Max: 51.61
Current: 51.61
During the past 12 years, the highest FCF Margin % of 3SBio was 51.61%. The lowest was 6.50%. And the median was 18.44%.
STU:83B's FCF Margin % is ranked better than 96.98% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs STU:83B: 51.61
3SBio FCF Margin % Related Terms
3SBio FCF Margin % Historical Data
* Premium members only.
The historical data trend for 3SBio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:83B vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, 3SBio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where 3SBio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio (STU:83B) has a FCF Margin % of 62.32% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 3SBio and its competitors. This is 238% above median its historical median of 18.44. Over the past decade, 3SBio's FCF Margin % has ranged from 6.50 to 51.61. According to the industry distribution chart, 3SBio ranks #29 out of 959 companies in the Biotechnology industry, placing it in the top 3%.
Is 3SBio's FCF Margin % too high?
3SBio's current FCF Margin % of 62.32% is 238% above median its 10-year median of 18.44. Over the past 10 years, this metric has ranged from a low of 6.50 to a high of 51.61. Based on the distribution chart, 3SBio ranks #29 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3SBio has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #29 out of 959 companies for FCF Margin %. This places 3SBio in the top 3% of its industry — outperforming the majority of peers. Historically, 3SBio's own FCF Margin % has ranged from 6.50 to 51.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 3SBio and its competitors. 3SBio's current FCF Margin % is 62.32%, which is 238% above median its own 10-year median of 18.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.51, compared to a current price of €1.73 — trading 14.5% above its estimated fair value. The current FCF Margin % is 62.32%, which is 238% above median its 10-year median of 18.44. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For 3SBio (STU:83B), the current FCF Margin % is 62.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.73 is trading 14.5% above its estimated GF Value™ of €1.51.
GuruFocus considers 3SBio to be Modestly Overvalued.
Key valuation signals for STU:83B:
FCF Margin %: 62.32% (238% above median its 10-year median of 18.44)
GF Value™: €1.51 vs. price of €1.73 (14.5% above fair value)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score
Get the complete analysis for STU:83B
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
